STEPHAN REYNIER

About STEPHAN REYNIER

Stephan Reynier serves as Chief Regulatory and Pharmaceutical Compliance Officer at Cellectis, where he holds a strategically important role in the company’s development of cell and gene therapy programs. His responsibilities include regulatory strategy, compliance, and quality assurance oversight for the UCART portfolio, as well as managing interactions with key health authorities such as the EMA and the FDA. In a highly regulated biotechnology environment, his role is essential to ensuring that clinical and regulatory pathways are aligned with the standards required for advanced therapeutic products. Reynier joined Cellectis in April 2011. He initially served as Head of Programs at Ectycell, a former Cellectis subsidiary, from 2011 to 2014, where he was responsible for managing and coordinating internal and external collaborative programs. That experience gave him hands-on exposure to the operational side of biotech program management and to the coordination challenges inherent in multi-partner, science-driven projects. Before joining Cellectis, he held senior positions at Voisin Consulting Life Sciences as Senior Director and at Gilead Sciences as European Associate Director Medical Affairs. In those roles, he developed and implemented regulatory strategies for drugs and biologics, with a strong emphasis on cell and gene therapy. This background positioned him at the intersection of regulatory affairs, medical affairs, and program execution, making him well suited to support innovative therapies through complex development pathways. Academically, Reynier graduated as an agro-engineer in France and earned a Master of Science in Chemical Engineering from the University of Toronto. His scientific and technical training provides a strong foundation for working across R&D, clinical development, and compliance functions. At Cellectis, he has been associated with major regulatory milestones for UCART candidates, reflecting his contribution to moving advanced therapeutic programs from early development toward clinical evaluation and, ultimately, toward potential patient access.